Immunomodulatory properties of mesenchymal stem cell in experimental arthritis in rat and mouse models: A systematic review.
Despite recent advances in the treatment of arthritis with the development of disease-modifying antirheumatic drugs, 30% of patients still fail to respond to treatment. Given the potent anti-inflammatory and immunomodulatory properties of mesenchymal stem cells (MSC) and their ability to repair damaged cartilage, bone, and tendons, it has been proposed that MSC could be ideal for cell-based treatment of arthritis.



This systematic review investigates evidence from studies on the therapeutic efficacy of MSC in rodent models of arthritis.



PubMed, Embase, MEDLINE, and Wed of Science were searched to June 2015 for quantitative studies examining the outcome of treating animal models of arthritis with MSC. Inclusion criteria were as follows: administration of mesenchymal stem as a treatment approach for arthritis; animal models only; and published in English. We followed the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines.



The literature search identified 30 studies which met the inclusion criteria. A range of MSC populations were assessed in various rodent models of arthritis. Of these, 19 demonstrated positive outcomes while 11 studies failed to demonstrate positive effects. Owing to the extensive variation in the experimental design, cells investigated and the outcome measures described in the manuscripts, no meta-analysis was possible. Furthermore, the numerical values for the primary outcome measure of clinical paw score were frequently not published in the manuscripts analyzed, as they were only illustrated in graphical form.



Numerous studies have investigated the utility of a range of MSC populations in the treatment of experimental arthritis. The results obtained from these studies have been highly inconsistent, with multiple studies identifying a statistically significant improvement in arthritis scores after treatment with MSC, while other studies identified a statistically significant deterioration in arthritis scores and thirdly some studies showed no effect. Further studies using standardized protocols and outcome measures are needed to determine fully the potential of MSC populations in the treatment of experimental arthritis.
Colgate Australian Dental Research Centre, Dental School, University of Adelaide, Adelaide, SA, Australia; School of Medicine, Faculty of Health Sciences, University of Adelaide, Adelaide, SA, Australia; South Australian Health and Medical Research Institute, Adelaide, SA, Australia. Electronic address: kim.hynes@adelaide.edu.au.
Kim
K
Hynes
Colgate Australian Dental Research Centre, Dental School, University of Adelaide, Adelaide, SA, Australia.
Richard
R
Bright
Rheumatology Unit, Royal Adelaide Hospital and Discipline of Medicine, University of Adelaide, SA, Australia.
Susanna
S
Proudman
South Australian Health and Medical Research Institute, Adelaide, SA, Australia.
David
D
Haynes
School of Medicine, Faculty of Health Sciences, University of Adelaide, Adelaide, SA, Australia; South Australian Health and Medical Research Institute, Adelaide, SA, Australia.
Stan
S
Gronthos
Colgate Australian Dental Research Centre, Dental School, University of Adelaide, Adelaide, SA, Australia.
Mark
M
Bartold
D000818:Animals; D001169:Arthritis, Experimental / Q000276:immunology / Q000628:therapy*; D056747:Immunomodulation / Q000276:immunology*; D045164:Mesenchymal Stem Cell Transplantation; D059630:Mesenchymal Stem Cells / Q000276:immunology*; D051379:Mice; D051381:Rats; D016896:Treatment Outcome
Anti-inflammatory; Arthritis; Cell therapy; Immunomodulation; Mesenchymal stem cells